Medizone Announces Completion of Financing

Kalamazoo, Michigan, January 31, 2018.  Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® system, today announced that it raised $250,000 of net proceeds from the completion of a financing transaction, which included the issuance of a $285,000 convertible note and the creation of a $10 million equity line of credit, with specialized investment funds L2 Capital LLC and SBI Investments LLC 2014-1, which is managed by New York-based Sea Otter Global Ventures, LLC (collectively, the “Funds”).  Medizone’s ability to access the equity line of credit is contingent on the effectiveness of a Registration Statement on Form S-1 covering the resale by the Funds of shares put to them.   Medizone intends to file the Registration Statement within the next few weeks.

Commenting on the financing, David A. Dodd, Chief Executive Officer of Medizone, stated, “This financing gives us much needed liquidity as we embark on the commercialization and market development of the AsepticSure® system. I would like to thank L2 and SBI for their flexibility and their accommodation of our need for a speedy closing.”

About Medizone International, Inc.

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

 

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 269-202-5020

E: [email protected]

For more information, visit:

www.medizoneint.com

Email: [email protected]

Medizone International Appoints Jude Dinges to Executive Team

Kalamazoo, Michigan, January 30, 2018.  Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® system, today announced the appointment of Jude P. Dinges, as its Executive Vice President – Commercial Operations.  Before joining Medizone, Mr. Dinges, served as Senior Vice President, Chief Commercial Officer of Aeterna Zentaris Inc.

“We are very excited to welcome Jude to our leadership team.  I have worked with Jude extensively in the past and, I am confident that Medizone will benefit greatly from his commercial leadership, experience and expertise,” said David Dodd, CEO of Medizone. “In his role, Jude will be an invaluable asset in establishing the commercial platform for the AsepticSure® system.”

Mr. Dinges added, “I am delighted to be joining Medizone at the ground floor of its efforts to commercialize the AsepticSure® system.  The Company has demonstrated the superiority of the AsepticSure® system as a means of addressing a wide variety of disinfection challenges.  My charge is to establish a commercial model that realizes the inherent value of the AsepticSure® system to operators of health facilities of all types and to other entities that face the risk of accidental infections.”

Jude Dinges’ Background

Mr. Dinges began his career nearly 35 years ago as a professional sales representative at Bristol Laboratories and later at Merck & Co., where he was promoted to positions with increased responsibilities in training, hospital & specialty sales, management, marketing and market development. Mr. Dinges won multiple leadership awards, including the President’s Achievement Award in 2001, awarded to one of 32 Business Directors each year.  He received the Change Agent Award for his market development prelaunch business planning and contributions to sales force execution, while launching the blockbuster brands Cozaar®, Fosamax®, Singulair®, Maxalt®, Vioxx®, and Vytorin®.  He was recognized with a Career Achievement Award for his consistent top performance as a Senior/Executive Business Director.  Mr. Dinges joined Novartis Pharmaceuticals in 2006 and led his region to top performance in the launch of Tekturna®. In 2009, Mr. Dinges joined Amgen Inc. as Executive Director of Region Sales, Bone Health Business Unit where he led his team to a highly successful launch of Prolia® across the southeastern United States and Puerto Rico.

About Medizone International, Inc.

Medizone International, Inc. is focused on commercializing the AsepticSure® system, a superior disinfectant technology compared to conventional systems or practices.  The company developed the AsepticSure® system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone.  After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act.  Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations.  The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]
For more information, visit:
www.medizoneint.com
Email: [email protected]

 

Medizone determines regulatory pathway for the AsepticSure® System, a revolutionary disinfection technology, following meeting with U.S. FDA

Kalamazoo, Michigan, January 18, 2018.  Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® system, today announced that as a result of its meeting with representatives of the U.S. Food and Drug Administration (“FDA”) on January 18, 2018, it has reached decisions regarding the regulatory pathway for approval of the system and the additional information that must be generated to support a marketing application.

Medizone’s President and Chief Medical Officer, Dr. Michael Shannon commented, “Our discussions with the FDA regarding the regulatory pathway for approval of AsepticSure® were positive, productive, detailed and specific.  During the discussions, the FDA stated its position that there is no predicate device that is substantially equivalent to AsepticSure® because of its unique method of action.  As a result, we will apply for De Novo classification of the system.  Furthermore, we now have a clear understanding of the additional testing that we will need to conduct and the additional data that we will need to submit to support our De Novo application. We anticipate being able to perform the additional testing and to provide the additional data within a few months, which would permit us to submit an application for De Novo classification by the end of the third quarter.  If our application for De Novo classification is granted, we believe we will enjoy a significant competitive advantage over other disinfection technologies.”

About Medizone International, Inc.

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 269-202-5020

E: [email protected]

For more information, visit:

http://www.medizoneint.com

Email: [email protected]

Medizone International Attending the J.P. Morgan 36th Annual Healthcare Conference for Partnership and Investment Discussions

KALAMAZOO, Mich., December 27, 2017: Medizone International, Inc. (OTCQB: MZEI) announced today the Company’s management will be attending the J.P. Morgan 36th Annual Healthcare Conference in San Francisco January 8th through 11th. Attending the conference will be Medizone’s CEO David Dodd and Medizone’s Chairman of the Board David Esposito. The company will be meeting with potential business partners and investment partners in support of the commercial development of AsepticSure®.

Medizone International, Inc., CEO David Dodd commented, “AsepticSure® represents a superior disinfectant technology compared to conventional systems or practices, providing over a thousand-times improvement in the reduction of pathogens, validated to disinfect to the sterilization standard of a 6-log reduction, representing greater than 99.9999% reduction.  To-date, our data demonstrates that AsepticSure® achieves 100% kill on 100% of surfaces, 100% of the time on 100% of pathogens – what we call the, ‘AsepticSure® 100% Rule’.  With the product approved for widespread commercialization, we are actively discussing with potential business partners and investment partners various options to achieve and grow AsepticSure® into the standard for disinfection and decontamination across multiple markets worldwide.”

 

About Medizone International, Inc.

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices.  The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone  released the AsepticSure® System for use in multiple markets worldwide.

 

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

 

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

 

Medizone International, Inc.

T: 01 269-202-5020

E: [email protected]

 

For more information, visit:

Email: [email protected]

Medizone International, Inc. (OTCQB: MZEI)

350 East Michigan Avenue – Suite 500
Kalamazoo, MI 49007

Telephone: (269) 202-5020

Email: [email protected]

Media and Investor Relations:

John Pentony

Medizone International, Inc.

Telephone: (269) 202-5020

Email: [email protected]

Social Media


Twitter:


https://twitter.com/asepticsure

CONTACT:

Medizone International, Inc. (OTCQB: MZEI)
350 East Michigan Avenue - Suite 500
Kalamazoo, MI 49007

Telephone: 269-202-5020

Email: [email protected]

INVESTOR & MEDIA RELATIONS:

John Pentony
Medizone International, Inc.

Telephone: (269) 202-5020

Email: [email protected]

SOCIAL MEDIA:

Medizone International on Twitter:

https://twitter.com/asepticsure